Jose Soto Soto, MD
Pulmonary Disease · Jacksonville, FLNPI 1275797177
Payments from drug & device makers
Across 437 payments — averaging $1256.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$381K
- Genentech USA, Inc.$88K
- AstraZeneca$37K
- Boehringer Ingelheim$20K
- Sanofi$14K
- Regeneron Healthcare Solutions, Inc.$4K
- plus $6K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 238 | $380,614 |
| Genentech USA, Inc. | 93 | $88,130 |
| AstraZeneca | 11 | $37,224 |
| Boehringer Ingelheim | 29 | $19,708 |
| Sanofi | 9 | $13,663 |
| Regeneron Healthcare Solutions, Inc. | 9 | $4,040 |
| Intuitive Surgical | 6 | $3,732 |
| Mallinckrodt Enterprises LLC | 4 | $468 |
| United Therapeutics Corporation | 6 | $386 |
| Actelion Pharmaceuticals US, Inc. | 5 | $279 |
| Insmed, Inc. | 3 | $163 |
| E.r. Squibb & Sons, L.L.C. | 2 | $130 |
| Inspire Medical Systems, Inc. | 1 | $128 |
| Verona Pharma, Inc. | 1 | $125 |
| Pulmonx Corporation | 1 | $97 |
| Boston Scientific | 1 | $59 |
| Mylan Specialty L.p. | 2 | $49 |
| Genentech, Inc. | 1 | $47 |
| Gilead | 2 | $43 |
| Philips North America LLC | 3 | $40 |
| AbbVie | 2 | $29 |
| Pfizer | 2 | $28 |
| Novartis | 2 | $27 |
| Shire North American Group Inc | 1 | $22 |
| Grifols USA, LLC | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $11 |
How this compares
$549,279 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Jacksonville
- Charles BurgerJacksonville$5.6M
- Abubakr BajwaJacksonville$1.4M
- Jennifer FultonJacksonville$791K
- Sebastian Fernandez-BussyJacksonville$559K
- Remzi BagJacksonville$556K
- Augustine LeeJacksonville$533K
- Jorge MalleaJacksonville$478K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.